TY - JOUR T1 - Impact of azithromycin mass drug administration on the antibiotic-resistant gut microbiome: a randomized, controlled trial JF - medRxiv DO - 10.1101/2021.03.02.20215632 SP - 2021.03.02.20215632 AU - Harry Pickering AU - John D. Hart AU - Sarah Burr AU - Richard Stabler AU - Ken Maleta AU - Khumbo Kalua AU - Robin L. Bailey AU - Martin J. Holland Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/03/03/2021.03.02.20215632.abstract N2 - Background Mass drug administration (MDA) with azithromycin is the primary strategy for global trachoma control efforts. Numerous studies have reported secondary effects of MDA with azithromycin, including reductions in childhood mortality, diarrhoeal disease and malaria. Most recently, the MORDOR clinical trial demonstrated that MDA led to an overall reduction in all-cause childhood mortality in targeted communities. There is however concern about the potential of increased antimicrobial resistance in treated communities.Methods This study evaluated the impact of azithromycin MDA on the prevalence of gastrointestinal carriage of macrolide-resistant bacteria in communities within the MORDOR Malawi study, additionally profiling changes in the gut microbiome after treatment. For faecal metagenomics, 60 children were sampled prior to treatment and 122 children after four rounds of MDA, half receiving azithromycin and half placebo.Findings The proportion of bacteria carrying macrolide resistance increased after azithromycin treatment; the effect was enhanced in children treated within six months of sampling. Diversity and global community structure of the gut was minimally impacted by treatment, however abundance of several species was altered by treatment. Notably, the putative human enteropathogen Escherichia albertii was more abundant after treatment.Interpretation The impacts of MDA with azithromycin, including increased carriage of macrolide-resistant bacteria, were enhanced in children treated more recently, suggesting effects may be transient. Increased abundance of enteropathogenic Escherichia species after treatment requires further, higher resolution investigation. Future studies should focus on the number of treatments and administration schedule to ensure clinical benefits continue to outweigh costs in antimicrobial resistance carriage.Funding Bill and Melinda Gates FoundationCompeting Interest StatementThe authors have declared no competing interest.Clinical TrialNCT02048007Funding StatementThis work was funded by the Bill and Melinda Gates Foundation under grant numbers OPP1066930 and OP1032340.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval for the MORDOR trials in Malawi was obtained from the College of Medicine Research and Ethics Committee, College of Medicine, University of Malawi (Malawi) and the London School of Hygiene and Tropical Medicine Observational/Interventions Research Ethics Committee, London School of Hygiene and Tropical Medicine (UK). Written, informed consent was obtained from the guardians of participants of all participating children. Illiterate guardians provided a thumb print to acknowledge consent.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll sequence data are available from the European Bioinformatics Institute (EBI) short read archive (PRJEB42363). ER -